Decongestants in Obstructive Sleep Apnoea (DOSA)
Research type
Research Study
Full title
Randomised controlled trial of nasal decongestants versus placebo to prolong treatment free periods from continuous positive airway pressure therapy in mild to moderate obstructive sleep apnoea
IRAS ID
239372
Contact name
Najib Rahman
Contact email
Sponsor organisation
University of Oxford
Eudract number
2018-000065-37
Duration of Study in the UK
2 years, 7 months, 31 days
Research summary
The study is looking at patients with diagnosed sleep apnoea who have already been using CPAP treatment for at least 6 months. The intention is to ask patients to stop using their CPAP treatment and be randomised to either a real nasal spray or placebo. Patients will then be advised to spray the nasal spray into each nostril and either side of their throat prior to bed every night. The primary outcome of the study to see how long it takes for the patient’s sleep apnoea symptoms to return. This treatment will only be given for a maximum of 4 weeks at which time the patient should re-start their CPAP treatment. If the patient feels that their symptoms have returned or we see they have from the remote monitoring system, they will be wearing on a nightly basis, we will contact the patient to restart their CPAP treatment also. This study will hopefully result in an alternative temporary therapy for those patients wishing to have a "break" from traditional sleep apnoea treatments for things such as holidays.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
18/NE/0365
Date of REC Opinion
24 Dec 2018
REC opinion
Further Information Favourable Opinion